Submitted:
22 November 2023
Posted:
23 November 2023
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Materials and methods
2.1. Formulation of functionalized mesoporous silica nanoparticles MSNs
2.2. Drug Loading
2.3. Chitosan coating o and Crosslinking to FMSN by glutaraldehyde
2.4. Camptothecin (CPT) Quantification
2.5. In vitro release assay
2.6. Hemolysis Assay
2.7. Characterization Techniques
2.8. Statistical Analysis
3. Result and Discussion
3.1. Formulation of NDDS
3.2. Characterization of Functionalized mesoporous silica NPs (FMSN)
3.2.1. Dynamic light scattering
3.2.2. Scanning Electron Microscopy
| Zeta Size (nm) | SEM Size (nm) | Zeta Potential (mV) | PDI | |
|---|---|---|---|---|
| FMSN | 217 | 180 | +40.32 | 0.426 |
| FMSN-CPT | 245 | 205 | +29.67 | 0.413 |
| FMSN-CPT-GA-CS (0.5%) | 278 | 230 | +44.25 | 0.663 |
| FMSN-CPT-GA-CS (1%) | 282 | 245 | +45.73 | 0.316 |
| FMSN-CPT-GA-CS (1.5%) | 343 | 311 | +44.61 | 1.625 |
3.2.3. Fourier-Transform Infrared Spectroscopy
3.2.4. BET surface analysis
3.2.5. Thermogravimetric Analysis
3.3. Drug Loading
3.4. Invitro Drug Release Kinetics
4. Hemolysis Assay
5. Conclusion
Author Contributions
Funding
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer Statistics, 2023. CA. Cancer J. Clin. 2023, 73, 17–48. [Google Scholar] [CrossRef] [PubMed]
- Sun, X.; Zhao, P.; Lin, J.; Chen, K.; Shen, J. Recent Advances in Access to Overcome Cancer Drug Resistance by Nanocarrier Drug Delivery System. Cancer Drug Resist. 2023, 6, 390–415. [Google Scholar] [CrossRef] [PubMed]
- Isa, E.D.M.; Ahmad, H.; Rahman, M.B.A.; Gill, M.R. Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment. Pharmaceutics 2021, 13, 1–33. [Google Scholar] [CrossRef] [PubMed]
- Hu, Y.; Bai, S.; Wu, X.; Tan, S.; He, Y. Biodegradability of Mesoporous Silica Nanoparticles. Ceram. Int. 2021, 47, 31031–31041. [Google Scholar] [CrossRef]
- Choi, E.; Kim, S. Surface PH Buffering to Promote Degradation of Mesoporous Silica Nanoparticles under a Physiological Condition. J. Colloid Interface Sci. 2019, 533, 463–470. [Google Scholar] [CrossRef] [PubMed]
- Koohi Moftakhari Esfahani, M.; Alavi, S.E.; Cabot, P.J.; Islam, N.; Izake, E.L. Application of Mesoporous Silica Nanoparticles in Cancer Therapy and Delivery of Repurposed Anthelmintics for Cancer Therapy. Pharmaceutics 2022, 14. [Google Scholar] [CrossRef] [PubMed]
- Jafernik, K.; Ładniak, A.; Blicharska, E.; Czarnek, K.; Ekiert, H.; Wiącek, A.E.; Szopa, A. Chitosan-Based Nanoparticles as Effective Drug Delivery Systems—A Review. Molecules 2023, 28, 1–17. [Google Scholar] [CrossRef] [PubMed]
- Alizadeh, L.; Alizadeh, E.; Zarebkohan, A.; Ahmadi, E.; Rahmati-Yamchi, M.; Salehi, R. AS1411 Aptamer-Functionalized Chitosan-Silica Nanoparticles for Targeted Delivery of Epigallocatechin Gallate to the SKOV-3 Ovarian Cancer Cell Lines. J. Nanoparticle Res. 2020, 22. [Google Scholar] [CrossRef]
- Sharifi-Rad, J.; Quispe, C.; Butnariu, M.; Rotariu, L.S.; Sytar, O.; Sestito, S.; Rapposelli, S.; Akram, M.; Iqbal, M.; Krishna, A.; et al. Chitosan Nanoparticles as a Promising Tool in Nanomedicine with Particular Emphasis on Oncological Treatment. Cancer Cell Int. 2021, 21, 1–21. [Google Scholar] [CrossRef]
- Procedures, E. Controlled Synthesis of Camptothecin - Polylactide Conjugates And. 2010, 111–121. [CrossRef]
- Li, Q.-Y.; Zu, Y.-G.; Shi, R.-Z.; Yao, L.-P. Review Camptothecin: Current Perspectives. Curr. Med. Chem. 2006, 13, 2021–2039. [Google Scholar] [CrossRef]
- Hu, J.K.; Suh, H.W.; Qureshi, M.; Lewis, J.M.; Yaqoob, S.; Moscato, Z.M.; Griff, S.; Lee, A.K.; Yin, E.S.; Mark Saltzman, W.; et al. Nonsurgical Treatment of Skin Cancer with Local Delivery of Bioadhesive Nanoparticles. Proc. Natl. Acad. Sci. USA 2021, 118, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Zahn, D.; Weidner, A.; Saatchi, K.; Häfeli, U.O.; Dutz, S. Biodegradable Magnetic Microspheres for Drug Targeting, Temperature Controlled Drug Release, and Hyperthermia. Curr. Dir. Biomed. Eng. 2019, 5, 161–164. [Google Scholar] [CrossRef]
- Bao, H.; Zhang, Q.; Yan, Z. The Impact of Camptothecin-Encapsulated Poly(Lactic-<em>co</Em>-Glycolic Acid) Nanoparticles on the Activity of Cytochrome P450 in Vitro. Int. J. Nanomedicine 2019, Volume 14, 383–391. [Google Scholar] [CrossRef]
- Fan, D.; Cao, Y.; Cao, M.; Wang, Y.; Cao, Y.; Gong, T. Nanomedicine in Cancer Therapy. Signal Transduct. Target. Ther. 2023, 8. [Google Scholar] [CrossRef]
- Yao, Y.; Zhou, Y.; Liu, L.; Xu, Y.; Chen, Q.; Wang, Y.; Wu, S.; Deng, Y.; Zhang, J.; Shao, A. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front. Mol. Biosci. 2020, 7, 1–14. [Google Scholar] [CrossRef] [PubMed]
- Landgraf, M.; Lahr, C.A.; Kaur, I.; Shafiee, A.; Sanchez-Herrero, A.; Janowicz, P.W.; Ravichandran, A.; Howard, C.B.; Cifuentes-Rius, A.; McGovern, J.A.; et al. Targeted Camptothecin Delivery via Silicon Nanoparticles Reduces Breast Cancer Metastasis. Biomaterials 2020, 240, 119791. [Google Scholar] [CrossRef]
- Gustavson, D.E.; Miyake, A. Mesoporous Silica Nanoparticle Delivery of Chemically Modified SiRNA Against TWIST1 Leads to Reduced Tumor Burden. Cogn. Emot. J. 2016, 30, 1289–1303. [Google Scholar] [CrossRef]
- Sæbø, I.P.; Bjørås, M.; Franzyk, H.; Helgesen, E.; Booth, J.A. Optimization of the Hemolysis Assay for the Assessment of Cytotoxicity. Int. J. Mol. Sci. 2023, 24. [Google Scholar] [CrossRef] [PubMed]
- Shakeran, Z.; Keyhanfar, M.; Varshosaz, J.; Sutherland, D.S. Biodegradable Nanocarriers Based on Chitosan-Modified Mesoporous Silica Nanoparticles for Delivery of Methotrexate for Application in Breast Cancer Treatment. Mater. Sci. Eng. C 2021, 118, 111526. [Google Scholar] [CrossRef]
- Busey, R.H.; Mesmer, R.E. / E. 1977, 16, 2444–2450. [CrossRef]
- Guo, L.; Chen, H.; He, N.; Deng, Y. Effects of Surface Modifications on the Physicochemical Properties of Iron Oxide Nanoparticles and Their Performance as Anticancer Drug Carriers. Chinese Chem. Lett. 2018, 29, 1829–1833. [Google Scholar] [CrossRef]
- Yoncheva, K.; Vandervoort, J.; Ludwig, A. Influence of Chitosan Layer on the Properties of Surface Modified Poly(Lactide-Co-Glycolide) Nanoparticles. J. Dispers. Sci. Technol. 2009, 30, 213–216. [Google Scholar] [CrossRef]
- Shah, P.V.; Rajput, S.J. Facile Synthesis of Chitosan Capped Mesoporous Silica Nanoparticles: A PH Responsive Smart Delivery Platform for Raloxifene Hydrochloride. AAPS PharmSciTech 2018, 19, 1344–1357. [Google Scholar] [CrossRef]
- Babaei, M.; Abnous, K.; Taghdisi, S.M.; Taghavi, S.; Sh. Saljooghi, A.; Ramezani, M.; Alibolandi, M. Targeted Rod-Shaped Mesoporous Silica Nanoparticles for the Co-Delivery of Camptothecin and Survivin ShRNA in to Colon Adenocarcinoma in Vitro and in Vivo. Eur. J. Pharm. Biopharm. 2020, 156, 84–96. [CrossRef]
- Buchman, J.T.; Elmer, W.H.; Ma, C.; Landy, K.M.; White, J.C.; Haynes, C.L. Chitosan-Coated Mesoporous Silica Nanoparticle Treatment of Citrullus Lanatus (Watermelon): Enhanced Fungal Disease Suppression and Modulated Expression of Stress-Related Genes. ACS Sustain. Chem. Eng. 2019, 7, 19649–19659. [Google Scholar] [CrossRef]
- Popat, A.; Liu, J.; Lu, G.Q.; Qiao, S.Z. A PH-Responsive Drug Delivery System Based on Chitosan Coated Mesoporous Silica Nanoparticles. J. Mater. Chem. 2012, 22, 11173–11178. [Google Scholar] [CrossRef]
- Carrera Espinoza, M.J.; Lin, K.S.; Weng, M.T.; Kunene, S.C.; Wang, S.S.-S. In Vitro Studies of Pluronic F127 Coated Magnetic Silica Nanocarriers for Drug Delivery System Targeting Liver Cancer. Eur. Polym. J. 2021, 153, 110504. [Google Scholar] [CrossRef]
- Jin, M.H.; Park, J.H.; Oh, D.; Park, J.S.; Lee, K.Y.; Lee, D.W. Effect of the Amine Group Content on Catalytic Activity and Stability of Mesoporous Silica Supported Pd Catalysts for Additive-Free Formic Acid Dehydrogenation at Room Temperature. Int. J. Hydrogen Energy 2019, 44, 4737–4744. [Google Scholar] [CrossRef]
- Subramanian, N.; Sundaraganesan, N.; Sudha, S.; Aroulmoji, V.; Sockalingam, G.D.; Bergamin, M. Experimental and Theoretical Investigation of the Molecular and Electronic Structure of Anticancer Drug Camptothecin. Spectrochim. Acta - Part A Mol. Biomol. Spectrosc. 2011, 78, 1058–1067. [Google Scholar] [CrossRef]
- Jackson, N.; Ortiz, A.C.; Jerez, A.; Morales, J.; Arriagada, F. Kinetics and Mechanism of Camptothecin Release from Transferrin-Gated Mesoporous Silica Nanoparticles through a PH-Responsive Surface Linker. Pharmaceutics 2023, 15. [Google Scholar] [CrossRef]
- Chen, G.; Mi, J.; Wu, X.; Luo, C.L.; Li, J.B.; Tang, Y.X.; Li, J. Structural Features and Bioactivities of the Chitosan. Int. J. Biol. Macromol. 2011, 49, 543–547. [Google Scholar] [CrossRef] [PubMed]
- Saini, K.; Bandyopadhyaya, R. Transferrin-Conjugated Polymer-Coated Mesoporous Silica Nanoparticles Loaded with Gemcitabine for Killing Pancreatic Cancer Cells. ACS Appl. Nano Mater. 2020, 3, 229–240. [Google Scholar] [CrossRef]
- Thahir, R.; Wahab, A.W.; Nafie, N.L.; Raya, I. Synthesis of High Surface Area Mesoporous Silica SBA-15 by Adjusting Hydrothermal Treatment Time and the Amount of Polyvinyl Alcohol. Open Chem. 2019, 17, 963–971. [Google Scholar] [CrossRef]
- Nairi, V.; Medda, S.; Piludu, M.; Casula, M.F.; Vallet-Regì, M.; Monduzzi, M.; Salis, A. Interactions between Bovine Serum Albumin and Mesoporous Silica Nanoparticles Functionalized with Biopolymers. Chem. Eng. J. 2018, 340, 42–50. [Google Scholar] [CrossRef]
- El-Hefian, E.A.; Nasef, M.M.; Yahaya, A.H. Preparation and Characterization of Chitosan/Agar Blended Films: Part 2. Thermal, Mechanical, and Surface Properties. E-Journal Chem. 2012, 9, 510–516. [Google Scholar] [CrossRef]
- Monsalve, Y.; Sierra, L.; López, B.L. Preparation and Characterization of Succinyl-Chitosan Nanoparticles for Drug Delivery. Macromol. Symp. 2015, 354, 91–98. [Google Scholar] [CrossRef]
- Lu, J.; Liong, M.; Zink, J.I.; Tamanoi, F. Mesoporous Silica Nanoparticles as a Delivery System for Hydrophobic Anticancer Drugs. Small 2007, 3, 1341–1346. [Google Scholar] [CrossRef]
- Llinàs, M.C.; Martínez-Edo, G.; Cascante, A.; Porcar, I.; Borrós, S.; Sánchez-García, D. Preparation of a Mesoporous Silica-Based Nano-Vehicle for Dual DOX/CPT Ph-Triggered Delivery. Drug Deliv. 2018, 25, 1137–1146. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.; Lin, Y.; Gillies, R.J. Tumor PH and Its Measurement. J. Nucl. Med. 2010, 51, 1167–1170. [Google Scholar] [CrossRef]
- Lu, J.; Liong, M.; Zink, J.I.; Tamanoi, F. Mesoporous Silica Nanoparticles as a Delivery System for Hydrophobic Anticancer Drugs. Small 2007, 3, 1341–1346. [Google Scholar] [CrossRef]
- Gan, Q.; Wang, T. Chitosan Nanoparticle as Protein Delivery Carrier-Systematic Examination of Fabrication Conditions for Efficient Loading and Release. Colloids Surfaces B Biointerfaces 2007, 59, 24–34. [Google Scholar] [CrossRef]
- Botella, P.; Abasolo, I.; Fernández, Y.; Muniesa, C.; Miranda, S.; Quesada, M.; Ruiz, J.; Schwartz, S.; Corma, A. Surface-Modified Silica Nanoparticles for Tumor-Targeted Delivery of Camptothecin and Its Biological Evaluation. J. Control. Release 2011, 156, 246–257. [Google Scholar] [CrossRef]
- Huarte, J.; Espuelas, S.; Lai, Y.; He, B.; Tang, J.; Irache, J.M. Oral Delivery of Camptothecin Using Cyclodextrin/Poly(Anhydride) Nanoparticles. Int. J. Pharm. 2016, 506, 116–128. [Google Scholar] [CrossRef] [PubMed]
- Fu, C.; Qin, J.; Liu, X.; Kong, F. Galactosed and Reduction-Responsive Nanoparticles Assembled from Trimethylchitosan–Camptothecin Conjugates for Enhanced Hepatocellular Carcinoma Therapy. Pharmaceutics 2022, 14. [Google Scholar] [CrossRef] [PubMed]
- Ye, Y.; Hu, X. A PH-Sensitive Injectable Nanoparticle Composite Hydrogel for Anticancer Drug Delivery. J. Nanomater. 2016, 2016. [Google Scholar] [CrossRef]
- Abedi, M.; Abolmaali, S.S.; Abedanzadeh, M.; Farjadian, F.; Samani, S.M.; Tamaddon, A.M. Core–Shell Imidazoline–Functionalized Mesoporous Silica Superparamagnetic Hybrid Nanoparticles as a Potential Theranostic Agent for Controlled Delivery of Platinum(II) Compound. Int. J. Nanomedicine 2020, 15, 2617–2631. [Google Scholar] [CrossRef] [PubMed]
- Hu, B.; Wang, J.; Li, J.; Li, S.; Li, H. Superiority of L-Tartaric Acid Modified Chiral Mesoporous Silica Nanoparticle as a Drug Carrier: Structure, Wettability, Degradation, Bio-Adhesion and Biocompatibility. Int. J. Nanomedicine 2020, 15, 601–618. [Google Scholar] [CrossRef]
- Harpe, K.; Kondiah, P.; Choonara, Y.; Marimuthu, T.; Toit, L.; Pillay, V. The Hemocompatibility of Nanoparticles : A Review. Cells 2019, 8, 1–25. [Google Scholar] [CrossRef]
- Yedgar, S.; Barshtein, G.; Gural, A. Hemolytic Activity of Nanoparticles as a Marker of Their Hemocompatibility. Micromachines 2022, 13, 1–15. [Google Scholar] [CrossRef]






| CS % | CS Initial (ml) | FMSN (mg) | Final (mg) @ Time Points (hr) | Gain (mg) @ Time Points (hr) | ||||
|---|---|---|---|---|---|---|---|---|
| 4 | 12 | 18 | 4 | 2 | 18 | |||
| 0.5 | 1 | 20 | 20.8 | 22 | 24 | 0.8 | 2 | 4 |
| 1 | 1 | 20 | 21.5 | 23 | 29 | 1.5 | 3 | 9 |
| 1.5 | 1 | 20 | 22.8 | 25 | 32 | 2.8 | 5 | 12 |
| BET Surface Area (m2/g) | BET Pore Volume (cm3/g) | BJH Pore dm (nm) | |
|---|---|---|---|
| MSN | 712.6392 | 0.45583 | 7-13 |
| FMSN-CPT-GA-CS | 415m2/g | 0.22 | - |
| NDDS | pH | Model | ||
|---|---|---|---|---|
| 0 Order | Korsmeyer-Peppas | Weibull Models | ||
| FMSN | 6.4 | 0.7006 | 0.9918 | 0.9950 |
| FMSN-CPT-CS(0.5) | 6.4 | 0.7652 | 0.9905 | 0.9930 |
| FMSN-CPT-CS(1) | 6.4 | 0.8288 | 0.9894 | 0.9915 |
| FMSN-CPT-CS(1.5) | 6.4 | 0.8026 | 0.9915 | 0.9924 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).